225 related articles for article (PubMed ID: 30467920)
1. Persistent restoration to the immunosupportive tumor microenvironment in glioblastoma by bevacizumab.
Tamura R; Tanaka T; Ohara K; Miyake K; Morimoto Y; Yamamoto Y; Kanai R; Akasaki Y; Murayama Y; Tamiya T; Yoshida K; Sasaki H
Cancer Sci; 2019 Feb; 110(2):499-508. PubMed ID: 30467920
[TBL] [Abstract][Full Text] [Related]
2.
Suzuki T; Takei J; Fukasawa N; Suzuki K; Ogawa D; Yamamoto Y; Akasaki Y; Murayama Y; Shimoda M; Miyake K; Tanaka T
World Neurosurg; 2023 Jul; 175():e1364-e1374. PubMed ID: 37187346
[TBL] [Abstract][Full Text] [Related]
3. CD44 expression in the tumor periphery predicts the responsiveness to bevacizumab in the treatment of recurrent glioblastoma.
Nishikawa M; Inoue A; Ohnishi T; Yano H; Kanemura Y; Kohno S; Ohue S; Ozaki S; Matsumoto S; Suehiro S; Nakamura Y; Shigekawa S; Watanabe H; Kitazawa R; Tanaka J; Kunieda T
Cancer Med; 2021 Mar; 10(6):2013-2025. PubMed ID: 33543833
[TBL] [Abstract][Full Text] [Related]
4. Status of alternative angiogenic pathways in glioblastoma resected under and after bevacizumab treatment.
Ezaki T; Tanaka T; Tamura R; Ohara K; Yamamoto Y; Takei J; Morimoto Y; Imai R; Kuranai Y; Akasaki Y; Toda M; Murayama Y; Miyake K; Sasaki H
Brain Tumor Pathol; 2024 Apr; 41(2):61-72. PubMed ID: 38619734
[TBL] [Abstract][Full Text] [Related]
5. Atezolizumab and Bevacizumab Attenuate Cisplatin Resistant Ovarian Cancer Cells Progression Synergistically via Suppressing Epithelial-Mesenchymal Transition.
Zhang L; Chen Y; Li F; Bao L; Liu W
Front Immunol; 2019; 10():867. PubMed ID: 31105696
[TBL] [Abstract][Full Text] [Related]
6. Toxicity and efficacy of lomustine and bevacizumab in recurrent glioblastoma patients.
Jakobsen JN; Urup T; Grunnet K; Toft A; Johansen MD; Poulsen SH; Christensen IJ; Muhic A; Poulsen HS
J Neurooncol; 2018 Apr; 137(2):439-446. PubMed ID: 29330749
[TBL] [Abstract][Full Text] [Related]
7. Increased tumour cell PD-L1 expression, macrophage and dendritic cell infiltration characterise the tumour microenvironment of ulcerated primary melanomas.
Koelblinger P; Emberger M; Drach M; Cheng PF; Lang R; Levesque MP; Bauer JW; Dummer R
J Eur Acad Dermatol Venereol; 2019 Apr; 33(4):667-675. PubMed ID: 30357969
[TBL] [Abstract][Full Text] [Related]
8. Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase II Study of Onartuzumab Plus Bevacizumab Versus Placebo Plus Bevacizumab in Patients With Recurrent Glioblastoma: Efficacy, Safety, and Hepatocyte Growth Factor and O
Cloughesy T; Finocchiaro G; Belda-Iniesta C; Recht L; Brandes AA; Pineda E; Mikkelsen T; Chinot OL; Balana C; Macdonald DR; Westphal M; Hopkins K; Weller M; Bais C; Sandmann T; Bruey JM; Koeppen H; Liu B; Verret W; Phan SC; Shames DS
J Clin Oncol; 2017 Jan; 35(3):343-351. PubMed ID: 27918718
[TBL] [Abstract][Full Text] [Related]
9. A Randomized Phase II Trial (TAMIGA) Evaluating the Efficacy and Safety of Continuous Bevacizumab Through Multiple Lines of Treatment for Recurrent Glioblastoma.
Brandes AA; Gil-Gil M; Saran F; Carpentier AF; Nowak AK; Mason W; Zagonel V; Dubois F; Finocchiaro G; Fountzilas G; Cernea DM; Chinot O; Anghel R; Ghiringhelli F; Beauchesne P; Lombardi G; Franceschi E; Makrutzki M; Mpofu C; Urban HJ; Pichler J
Oncologist; 2019 Apr; 24(4):521-528. PubMed ID: 30266892
[TBL] [Abstract][Full Text] [Related]
10. Malignant pleural mesothelioma immune microenvironment and checkpoint expression: correlation with clinical-pathological features and intratumor heterogeneity over time.
Pasello G; Zago G; Lunardi F; Urso L; Kern I; Vlacic G; Grosso F; Mencoboni M; Ceresoli GL; Schiavon M; Pezzuto F; Pavan A; Vuljan SE; Del Bianco P; Conte P; Rea F; Calabrese F
Ann Oncol; 2018 May; 29(5):1258-1265. PubMed ID: 29514216
[TBL] [Abstract][Full Text] [Related]
11. Differences in PD-L1-Expressing Macrophages and Immune Microenvironment in Testicular Germ Cell Tumors.
Sadigh S; Farahani SJ; Shah A; Vaughn D; Lal P
Am J Clin Pathol; 2020 Feb; 153(3):387-395. PubMed ID: 31802108
[TBL] [Abstract][Full Text] [Related]
12. Differences in tumor microenvironments between primary lung tumors and brain metastases in lung cancer patients: therapeutic implications for immune checkpoint inhibitors.
Kim R; Keam B; Kim S; Kim M; Kim SH; Kim JW; Kim YJ; Kim TM; Jeon YK; Kim DW; Chung DH; Lee JS; Heo DS
BMC Cancer; 2019 Jan; 19(1):19. PubMed ID: 30616523
[TBL] [Abstract][Full Text] [Related]
13. Characterization of the Immune Microenvironment in Hepatocellular Carcinoma.
Yarchoan M; Xing D; Luan L; Xu H; Sharma RB; Popovic A; Pawlik TM; Kim AK; Zhu Q; Jaffee EM; Taube JM; Anders RA
Clin Cancer Res; 2017 Dec; 23(23):7333-7339. PubMed ID: 28928158
[No Abstract] [Full Text] [Related]
14. Alterations of the tumor microenvironment in glioblastoma following radiation and temozolomide with or without bevacizumab.
Tamura R; Tanaka T; Morimoto Y; Kuranari Y; Yamamoto Y; Takei J; Murayama Y; Yoshida K; Sasaki H
Ann Transl Med; 2020 Mar; 8(6):297. PubMed ID: 32355741
[TBL] [Abstract][Full Text] [Related]
15. Plasmablastic Lymphomas: Characterization of Tumor Microenvironment Using CD163 and PD-1 Immunohistochemistry.
Ahn JS; Al-Habib A; Vos JA; Sohani AR; Barboza-Quintana O; Flores JP; Wen S; Rosado FG
Ann Clin Lab Sci; 2020 Mar; 50(2):213-218. PubMed ID: 32366559
[TBL] [Abstract][Full Text] [Related]
16. Clinical outcomes in recurrent glioblastoma with bevacizumab therapy: An analysis of the literature.
Tipping M; Eickhoff J; Ian Robins H
J Clin Neurosci; 2017 Oct; 44():101-106. PubMed ID: 28711289
[TBL] [Abstract][Full Text] [Related]
17. Noninvasive Characterization of Tumor Angiogenesis and Oxygenation in Bevacizumab-treated Recurrent Glioblastoma by Using Dynamic Susceptibility MRI: Secondary Analysis of the European Organization for Research and Treatment of Cancer 26101 Trial.
Kickingereder P; Brugnara G; Hansen MB; Nowosielski M; Pflüger I; Schell M; Isensee F; Foltyn M; Neuberger U; Kessler T; Sahm F; Wick A; Heiland S; Weller M; Platten M; von Deimling A; Maier-Hein KH; Østergaard L; van den Bent MJ; Gorlia T; Wick W; Bendszus M
Radiology; 2020 Oct; 297(1):164-175. PubMed ID: 32720870
[TBL] [Abstract][Full Text] [Related]
18. The Importance of a Conjoint Analysis of Tumor-Associated Macrophages and Immune Checkpoints in Pancreatic Cancer.
Xu JY; Wang WS; Zhou J; Liu CY; Shi JL; Lu PH; Ding JL
Pancreas; 2019 Aug; 48(7):904-912. PubMed ID: 31268976
[TBL] [Abstract][Full Text] [Related]
19. Effect of bevacizumab against cystic components of brain tumors.
Yamasaki F; Kolakshyapati M; Takano M; Yonezawa U; Nishibuchi I; Imano N; Taguchi A; Onishi S; Amatya VJ; Takeshima Y; Nagata Y; Kurisu K; Sugiyama K
Cancer Med; 2019 Nov; 8(15):6519-6527. PubMed ID: 31498567
[TBL] [Abstract][Full Text] [Related]
20. Prognostic factors in recurrent glioblastoma patients treated with bevacizumab.
Schaub C; Tichy J; Schäfer N; Franz K; Mack F; Mittelbronn M; Kebir S; Thiepold AL; Waha A; Filmann N; Banat M; Fimmers R; Steinbach JP; Herrlinger U; Rieger J; Glas M; Bähr O
J Neurooncol; 2016 Aug; 129(1):93-100. PubMed ID: 27193554
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
